Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q2 FY23 results · Jul–Sep 2022
Aarti Drugs reported revenue from operations of ₹687.72 crore (up 18.7% from Q2 FY22) and net profit of ₹38.74 crore (down 9.0% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 687.72 | 579.62 | +18.7% | 621.96 | +10.6% |
| Other income | 0.05 | 0.08 | −37.5% | 0.26 | −80.8% |
| Total income | 687.77 | 579.70 | +18.6% | 622.22 | +10.5% |
| Profit before tax | 53.19 | 56.08 | −5.2% | 48.03 | +10.7% |
| Net profit for the period | 38.74 | 42.58 | −9.0% | 34.78 | +11.4% |
| Attributable to shareholders of the company | 38.75 | 42.59 | −9.0% | 34.79 | +11.4% |
| EPS, basic (₹) | 4.18 | 4.60 | −9.1% | 3.76 | +11.2% |
| Net margin (%) | 5.6 | 7.3 | 5.6 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 624.83 | 510.70 | +22.3% | 551.20 | +13.4% |
| Other income | 0.09 | 0.89 | −89.9% | 0.24 | −62.5% |
| Total income | 624.92 | 511.59 | +22.2% | 551.44 | +13.3% |
| Profit before tax | 50.08 | 53.11 | −5.7% | 36.35 | +37.8% |
| Net profit for the period | 36.58 | 40.61 | −9.9% | 26.35 | +38.8% |
| EPS, basic (₹) | 3.95 | 4.39 | −10.0% | 2.85 | +38.6% |
| Net margin (%) | 5.9 | 8.0 | 4.8 |
Consolidated
- Filed with BSE
- 22 Oct 2022, 12:06 IST
- Board meeting
- 20 Oct 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 Oct 2022, 12:06 IST
- Board meeting
- 20 Oct 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Audited
- Source
- XBRL filing on BSE